Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse

doi:10.2337/dci18-0033

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse

Institut for Klinisk Medicin

990 Citationer (Scopus)

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

Originalsprog	Engelsk
Tidsskrift	Diabetes Care
Vol/bind	41
Udgave nummer	12
Sider (fra-til)	2669-2701
Antal sider	33
ISSN	0149-5992
DOI	https://doi.org/10.2337/dci18-0033
Status	Udgivet - 1 dec. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.2337/dci18-0033

2669.full.pdfForlagets udgivne version, 3,31 MB

Citationsformater

Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018). Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41(12), 2669-2701. https://doi.org/10.2337/dci18-0033

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). / Davies, Melanie J; D'Alessio, David A; Fradkin, Judith et al.
I: Diabetes Care, Bind 41, Nr. 12, 01.12.2018, s. 2669-2701.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Davies, MJ, D'Alessio, DA, Fradkin, J, Kernan, WN, Mathieu, C, Mingrone, G, Rossing, P, Tsapas, A, Wexler, DJ & Buse, JB 2018, 'Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)', Diabetes Care, bind 41, nr. 12, s. 2669-2701. https://doi.org/10.2337/dci18-0033

@article{e2d8849a65824af7b4b61b378a7e2a34,

title = "Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)",

abstract = "The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.",

keywords = "Adult, Consensus, Diabetes Mellitus, Type 2/blood, Europe, Humans, Hyperglycemia/blood, Hypoglycemic Agents/classification, Life Style, Obesity/complications, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, United States, Weight Loss",

author = "Davies, {Melanie J} and D'Alessio, {David A} and Judith Fradkin and Kernan, {Walter N} and Chantal Mathieu and Geltrude Mingrone and Peter Rossing and Apostolos Tsapas and Wexler, {Deborah J} and Buse, {John B}",

note = "{\textcopyright} 2018 American Diabetes Association and European Association for the Study of Diabetes.",

year = "2018",

month = dec,

day = "1",

doi = "10.2337/dci18-0033",

language = "English",

volume = "41",

pages = "2669--2701",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "12",

}

TY - JOUR

T1 - Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

AU - Davies, Melanie J

AU - D'Alessio, David A

AU - Fradkin, Judith

AU - Kernan, Walter N

AU - Mathieu, Chantal

AU - Mingrone, Geltrude

AU - Rossing, Peter

AU - Tsapas, Apostolos

AU - Wexler, Deborah J

AU - Buse, John B

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

AB - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

KW - Adult

KW - Consensus

KW - Diabetes Mellitus, Type 2/blood

KW - Europe

KW - Humans

KW - Hyperglycemia/blood

KW - Hypoglycemic Agents/classification

KW - Life Style

KW - Obesity/complications

KW - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use

KW - United States

KW - Weight Loss

U2 - 10.2337/dci18-0033

DO - 10.2337/dci18-0033

M3 - Journal article

C2 - 30291106

SN - 0149-5992

VL - 41

SP - 2669

EP - 2701

JO - Diabetes Care

JF - Diabetes Care

IS - 12

ER -

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater